<DOC>
	<DOC>NCT01146522</DOC>
	<brief_summary>This study will assess safety, tolerability, and effect of LCQ908 on blood lipids in patients with severe hypertriglyceridemia.</brief_summary>
	<brief_title>Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<criteria>Patients with hyperlipoproteinemia Type I or Type V willing and medically able to discontinue their lipid lowering medication (if prescribed). Non breast feeding women. Women of child bearing potential practicing appropriate contraception with a negative pregnancy test before dosing. Patients with: uncontrolled type 1 or type 2 diabetes mellitus, active pancreatitis (the month prior to study start), history of drug or alcohol abuse within the 12 months prior to dosing, or any surgical or medical condition, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Familial hyperchylomicronemia</keyword>
	<keyword>Lipoprotein lipase deficiency</keyword>
	<keyword>Hyperlipoproteinemia</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>LCQ908</keyword>
	<keyword>Hyperlipoproteinemia associated with lipoprotein lipase deficiency</keyword>
</DOC>